As COVID-19 precautions are dwindling throughout the world, this upcoming flu season could re-heighten those precautions.
As COVID-19 precautions are dwindling throughout the world, this upcoming flu season could re-heighten those precautions, according to Richard Webby, Ph.D, a member of the Infectious Diseases Department at St. Jude Children’s Research Hospital and the World Health Organization’s Influenza Vaccine Composition Advisory Team.
While much of the world was in lockdown and taking precautions against COVID-19, there was virtually no flu season, Webby said.
“Many of the measures we used such as hand washing, disinfecting surfaces, and wearing masks to protect ourselves against COVID were also responsible for preventing influenza," he said. "But this lull in flu activity is only temporary; it is possible we may see the flu virus roaring back with a vengeance starting this fall as we relax these preventative measures.”
Epidemiologist Lauren Ancel Meyers, director of the University of Texas Covid-19 Modeling Consortium, told CNBC since our Covid mitigation measures prevented influenza transmission last year, there aren't many people who were recently infected.
In a recent paper authored by Webby, Nature Communications, he argues that mitigation efforts, such as social distancing, mask wearing and washing hands has helped reduce flu activity this season. Drawing off the experience of New Zealand, he also suggests in the paper that some of these same protocols – including lockdowns, border closers and other related measures – could help control future pandemics.
“We will be watching what happens in the Southern Hemisphere to see how much flu activity is starting to occur," he said. "If flu activity starts to rise in the Southern Hemisphere, it will give us a critical preview of what may be headed our way in the United States and how we can take early, precautionary steps to mitigate the impact. Right now flu activity is still low, but RSV (Respiratory Syncytial Virus) - a respiratory virus that was also pushed out by COVID precautions - is hitting Australia and New Zealand particularly hard."
According to a recent Time Magazine summary, this summer, RSV cases are spiking, particularly in southern states in the U.S. Around 2,000 confirmed cases were recorded during the week of July 10, 2021, compared to less than a dozen during the week of July 25, 2020. The actual number of infections is likely higher, since clinicians may not test sick children for RSV outside its usual season, the U.S. Centers for Disease Control and Prevention (CDC) said in a recent advisory.
When the pandemic hit, sending people inside and behind masks, respiratory illnesses like RSV circulated at “historically low levels,” the CDC said in a report. Now that people are easing up on COVID-19 precautions, they are also coming back into contact with pathogens that have existed, but weren’t spreading much, throughout the pandemic. RSV infections began to tick upward in April 2021, the CDC said.
RSV is transmissible, more so than some other viruses, CDC said. But one reason for the surge may be that children who typically wouldn’t be susceptible to RSV are vulnerable this year.
Typically, the CDC says, almost all children catch RSV in their first two years of life, but babies who were born during or shortly before the pandemic may not have encountered RSV as they usually would have, meaning they’re more susceptible to it now.
However, symptoms can be monitored and are no reason to panic. These include mild symptoms like a runny nose, coughing and sneezing — but if a child has trouble breathing, is very lethargic or can’t keep down food or water, they should see a doctor. Adults infected with RSV usually develop nothing more than cold-like symptoms, but elderly adults should be on the lookout for more severe issues, like dehydration or trouble breathing, according to the article.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
35th World AIDS Day Marks 20 Years of PEPFAR: Challenges and Strategies to Combat HIV/AIDS
November 29th 2023PEPFAR, having invested $100 billion and saved 25 million lives in the global fight against HIV/AIDS, faces Congressional hurdles in its reauthorization due to abortion debates. Despite widespread support and no evidence of abortion-related activities, the legislative process is at a standstill. Members of PEPFAR and authors of a recent editorial stress the significance of PEPFAR and advocate for integrating behavioral and social science into healthcare programs to achieve UNAIDS targets and address barriers in HIV/AIDS testing and treatment.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
Study Raises Concerns Over Insurance Barriers to HIV Prevention Medications
November 29th 2023Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.
Read More